![]() The preparation should be retained in the mouth as long as possible before swallowing.Ĭontinue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of Candida albicans. CHILDREN AND ADULTSĤ to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective. Nystatin Oral Suspension Dosage and Administration INFANTSĢ mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes). There have been no reports of serious toxic effects of superinfections (see CLINICAL PHARMACOLOGY, Pharmacokinetics). Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. Other: Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported. Stevens-Johnson syndrome has been reported very rarely. Gastrointestinal: Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.ĭermatologic: Rash, including urticaria has been reported rarely. ![]() Oral irritation and sensitization have been reported. Nystatin is well tolerated even with prolonged therapy. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman. It is not known whether nystatin is excreted in human milk. Nystatin Oral Suspension should be given to a pregnant woman only if clearly needed. It is also not known whether Nystatin Oral Suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Pregnancy Teratogenic Effects Category CĪnimal reproduction studies have not been conducted with Nystatin Oral Suspension. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females. No long-term animal studies have been performed to evaluate carcinogenic potential. Carcinogenesis, Mutagenesis, Impairment of Fertility Discontinue treatment if sensitization or irritation is reported during use. This medication is not to be used for the treatment of systemic mycoses. The preparation is contraindicated in patients with a history of hypersensitivity to any of its components. Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity. Indications and Usage for Nystatin Oral Suspension Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses. Nystatin acts by binding to sterols in the cell membrane of susceptible Candida species with a resultant change in membrane permeability allowing leakage of intracellular components. Generally, resistance does not develop in vivo. Candida albicans demonstrates no significant resistance to nystatin in vitro on repeated subculture in increasing levels of nystatin other Candida species become quite resistant. ![]() Nystatin is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur. Most orally administered nystatin is passed unchanged in the stool. Gastrointestinal absorption of nystatin is insignificant. Related/similar drugs fluconazole, nystatin, clotrimazole, Diflucan, itraconazole, miconazole, Mycostatin Nystatin Oral Suspension - Clinical Pharmacology Pharmacokinetics
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |